0.38
+12.01%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dyadic International
From its filings with the US Securities and Exchange Commission
Dyadic International is based in Jupiter, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DYAI. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $3.1m and a net loss of $7.4m. At that date it held total assets of $9.9m and shareholders' equity of $1.2m.
BASF SE, Codexis, Inc., and others, for use in industrial (non-pharmaceutical) applications.
Dapibus™ platform supports applications in life sciences, food and nutrition, and bio-industrial sectors.
T7 RNA polymerase, DNA ligase, and polymerases, with ongoing optimization and evaluation for research and diagnostic applications.
Vaccine Hub (EVH): Participation in a multi-country initiative to strengthen pandemic preparedness and vaccine development infrastructure.
Participation in a CEPI-supported Middle East Respiratory Syndrome coronavirus vaccine program.
C1 cell line used in the successfully completed DYAI-100 SARS-CoV-2 vaccine Phase 1 clinical study.
Bio-Industrial markets, such as our commercialization agreement with Fermbox to produce cellulosic enzyme solutions for biomass processing.
Industry standard for complex biologics but limited by long development cycles, high production costs, and complex purification requirements.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Nov 2004
- Employees
- 5
- Website
- dyadic.com ↗
- Head office
- 1044 NORTH U.S. HIGHWAY ONE, JUPITER, FL, 33477
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Patrick LucyIndependent Chairman of the Board$152,118
- Mr. Joseph HazeltonPresident, Chief Operating Officer$478,212
- Mr. Mark EmalfarbChief Executive Officer, Director, since 2004$1.0m
- Ms. Ping RawsonChief Financial Officer$419,127
- Dr. Ronen TcheletVice President - Research and Business Development$423,701
- Dr. Seth HerbstIndependent Director$126,480
- Mr. Jack KayeIndependent Director$157,923
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 48
- Social
- 75
- Governance
- 21
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Dyadic International Inc possesses several strengths that contribute to its success in the market. Firstly, the company has a reputation for top-notch research and development capabilities, allowing them to continuously innovate and develop new products. This puts them at the forefront of technological advancements in their industry. Additionally, Dyadic has a strong and experienced management team that provides effective leadership and strategic guidance to the company.
- Another significant strength is Dyadic's extensive network of partnerships and collaborations with leading organizations in various industries. This network not only enhances their market reach but also facilitates knowledge sharing and access to valuable resources. Furthermore, the company has a diverse portfolio of intellectual property rights, including patents and trademarks, which provide them with a competitive advantage and protect their innovations.
Weaknesses
- Despite its strengths, Dyadic International Inc also faces several weaknesses that pose challenges to its growth and profitability. One notable weakness is the company's dependence on a limited number of key customers. Any significant loss of these customers could have a substantial negative impact on Dyadic's revenue and overall financial performance.
- Additionally, Dyadic operates in a highly competitive industry where the barriers to entry are relatively low. This intensifies competition and puts pressure on the company to constantly differentiate itself and innovate to maintain its market position. Moreover, the company's heavy reliance on research and development for product development requires substantial investment, which may strain financial resources.
Opportunities
- Despite the challenges, Dyadic International Inc can leverage certain opportunities to enhance its growth prospects. The growing demand for biopharmaceuticals and therapeutic solutions presents a significant opportunity for the company to expand its market presence. By capitalizing on this trend and investing in product development, Dyadic can tap into new revenue streams.
- Furthermore, the increasing need for sustainable and environmentally friendly solutions opens doors for Dyadic to leverage its expertise in enzyme technologies. The company can explore collaborations with companies in industries such as biofuels, renewable chemicals, and agriculture to develop innovative and eco-friendly products.
Threats
- In addition to opportunities, Dyadic International Inc faces certain threats that could hinder its growth and success. One significant threat is the potential emergence of new competitors with disruptive technologies or alternative solutions. This could lead to increased competition and decreased market share for Dyadic.
- Moreover, the company operates in a global market influenced by economic and political uncertainties. Fluctuations in exchange rates, trade policies, and regulatory changes can impact Dyadic's international operations and profitability. Additionally, the legal and regulatory landscape surrounding intellectual property rights can also pose threats if infringements on Dyadic's patents or trademarks occur.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.